PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neurologyNeurologyAmerican Academy of Neurology
 
Neurology. 2013 March 12; 80(11 Suppl 3): S49–S53.
PMCID: PMC3662342

Pain assessment using the NIH Toolbox

Karon F. Cook, PhD,corresponding author

Scientific Advisory Boards:

  1. 1. Focus on Therapeutic Outcomes (FOTO), Scientific Advisory Board

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. Quality of Life Research, Associate Editor

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. Invivodata, XenoPort, Focus on Therapeutic Outcomes (FOTO), Boston University, University of Buffalo

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Winnie Dunn, PhD, OTR, FAOTA,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. (1)Family Infant Parent Program, travel + honorarium, (2) Israel Government, travel + honorarium, (3) Holland Therapy, travel + honorarium, (4) Middletown Autism Society, travel + honorarium, (5) University of Wisconsin, travel + honorarium, (6)OT Australia, travel + honorarium, (7) R2K Conference workgroup, travel + honorarium, (8)Helen Elsass Center, travel + honorarium

Editorial Boards:

  1. (1) Infants and Young Children, editorial board 2009 to present, (2) Autism, invited reviewer, 2010 to present

Patents:

  1. NONE

Publishing Royalties:

  1. Sensory Profile (1999), Adolescent Adult Sensory Profile (2002), Infant Toddler Sensory Profile (2002), Sensory Profile School Companion (2006), all from Pearson Publishing, Inc., (2) Living Sensationally understanding your senses (2009), Jessica Kingsley Publications, Best Practice Occupational Therapy for chidren and families in community settings, Brining Evidence into Everyday Practice, Measuring Occupational Performance, all from Slack Inc.

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. (1) EBS

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. (1) Advisory Committee Slack Inc.

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. (1) Kansas Center for Autism Research and Training

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
James W. Griffith, PhD,

Scientific Advisory Boards:

  1. I currently serve on one data safety monitoring board of a clinical trial for patients with bone loss. (DoD Grant # SC090010 - Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury.)

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. I received travel and speaking money/honoraria for scientific meetings as part of my role in the Multidisciplinary Assessment of Pelvic Pain (MAPP) research network from non-profit entities: the National Institutes of Health and the International Pelvic Pain Society. In both cases, the money I received was transferred to my department.

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. As part of my post at Northwestern University, I have received funding from Teva Neuroscience

Research Support, Government Entities:

  1. In addition to my position at Northwestern University, I have received support from the Research Foundation Flanders (FWO; GP.035.11N). For my post at Northwestern University, I have received funding from the following U.S.A. grants and contracts: MAPP Grant# U01 DK082342; The NIH Toolbox for Neurological and Behavioral Function, contract# HHS-N-260-2006-00007-C; DoD Grant # SC090010 - Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury; Neuro-QOL-Quality of Life Outcomes in Neurological Disorders, National Institute of Neurological Disorders and Stroke, (contract # HHSN265200423601C); Eastern Cooperative Oncology Group (ECOG) CA 37403

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
M. Tracy Morrison, OTD R/L,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Jennifer Tanquary,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Dory Sabata, OTD, OTR, SCEM,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. (1) Kansas Occupational Therapy Association, speaker honoraria

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. (1) University of Southern California

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. SLACK Inc., OT advisory board member for publishing company

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
David Victorson, PhD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. Dr. Victorson received an honoraria for serving on the Steering Committee of the Reeve Neuro-Recovery Network

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. Dr. Victorson was funded by NIH contracts #HHSN265200423601C and #HHS-N-260-2006-00007-C and grants #R01HD054569-02NIDRR, #1U01NS056975-01, #R01 CA104883, received support from the American Cancer Society (Illinois Division) for research in prostate cancer, received institutional support from NorthShore University HealthCare System for research in prostate cancer, and received institutional support from the Northwestern Medical Faculty Foundation for urology research.

Consultancies:

  1. Dr. Victorson received institutional support from the Medical University of South Carolina for consulting on sarcoidosis research.

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. Dr. Victorson was funded by NIH contracts #HHSN265200423601C and #HHS-N-260-2006-00007-C and grants #R01HD054569-02NIDRR, #1U01NS056975-01, #R01 CA104883,

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. Dr. Victorson received support from the American Cancer Society (Illinois Division) for research in prostate cancer,

Stock/Stock Options/Board of Directors Compensation:

  1. Dr. Victorson holds stock options in Eli Lily and Company

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Leeanne M. Carey, PhD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. Neurorehabilitation and Neural Repair, editorial board Occupational Therapy International, editorial board Australian Occupational Therapy Journal, editorial board (No compensation received. current. Uncertain re starting year.)

Patents:

  1. NONE

Publishing Royalties:

  1. Stroke Rehabilitation: Insights from Neuroscience and Imaging. 2012.(no royalties received at this stage)

Employment, Commercial Entity:

  1. Australian Research Council Future Fellowship (#FT0992299) and was previously supported by a National Health and Medical Research Council of Australia Career Development Award (#307905)

Consultancies:

  1. National Institute of Health Toolbox Project, expert consultant

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. Australian Research Council, Future Fellowship, grant #FT0992299, research scholarship, 2009-2013 National Health and Medical Research Council (of Australia) Career Development Award, #307905, research scholarship, 2004-2008.

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Joy C. MacDermid, BScPT, MSc, PhD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. associate editor journal of orthopaedic and sports physical therapy and journal of hand therapy

Patents:

  1. NONE

Publishing Royalties:

  1. evidence-based rehabilitation slack 2008

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. CIHR multiple operating grants

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Brian J. Dudgeon, PhD, OTR,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
and Richard C. Gershon, PhD

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. American Board of Podiatric Surgery Rockman et al. Sylvan Learning

Speakers' Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. National Institutes of Neurological Disorders and Stroke, HHSN 265200436, Co-Investigator, 2004-2009; National Institute of Arthritis and Musculoskeletal and Skin Diseases, U01 AR 052 177, Co-Investigator, 2004-2009; Heart, Lung and Blood Institute R01HL81485-03, Co-Investigator, 2005-2008; National Institutes of Health, U01 AR052177-01S1, Co-Investigator, 2005-2009; National Institutes of Health, CA 60068-11, Co-Investigator, 2005-2009; Centers for Medicare and Medicaid Services (CMS), “Post-Acute Care: Patient-Assessment Instrument Development”, Site Principal Investigator, 2006-2008; National Institutes of Health, AG-260-06-01, Principal Investigator, 2006-2011; National Institutes of Neurological Disorders and Stroke, U01 NS 056 975 02, Co-Investigator, 2006-2011; National Institutes of Health,5U01AR052171-04, Site Principal Investigator, 2007-2008; NIDRR, H133B040032, Site Principal Investigator, 2007-2009;NIDRR, “Quality of Life in Traumatic Brain Injury Research and Practice: Development of the TBI-QO,” Site Principal Investigator, 2007-2010; National Institutes of Health, HD05469, Site Principal Investigator, 2007-2012; National Institutes of Health, NHLBI K23 Award, Co-Investigator, 2007-2012; National Cancer Institute, CA 60068-13, Co-Investigator, 2007-2009; National Institutes of Health, “Interactive Mechanisms of Pelvic Pain,” Site Principal Investigator, 2008-2013; National Institutes of Health. Modification No 005, HHSN260200600007, N01-AG-6-0007, Principal Investigator, 2008-2011; National Institutes of Health, Modification No 005, HHSN260200600007, N01-AG-6-0007, Principal Investigator, 2008-2011; National Institutes on Aging, 1RC2AG036498-01, Principal Investigator, 2009-2011; National Institutes of Health Roadmap Initiative, “PROMIS Technical Center”, Principal Investigator, 2009-2013; NIDRR, “RRTC Measuring Rehabilitation Outcomes and Effectiveness”, Site Principal Investigator, 2010-2014; National Institutes of Health, “OMB Extension for NIH Toolbox for Assessment of Neurological and Behavioral Function”, Principal Investigator, 2011; OppNet, the NIH Basic Behavioral and Social Science Opportunity Network Principal Investigator, “Extended Norming for the NIH Toolbox for Assessment of Neurological and Behavioral Function”, 2011-2012; A Community Health Applied Research Network (CHARN) funded under the Health Resources and Services Administration (HRSA-10-154), Co-Investigator, 2010-2013

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. American Cancer Society, RSG-01-221-01-PBP, Co-Investigator, 2003-2006

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Abstract

Objective:

Pain is an important component of health and function, and chronic pain can be a problem in its own right. The purpose of this report is to review the considerations surrounding pain measurement in the NIH Toolbox, as well as to describe the measurement tools that were adopted for inclusion in the NIH Toolbox assessment battery.

Methods:

Instruments to measure pain in the NIH Toolbox were selected on the basis of scholarly input from a diverse group of experts, as well as review of existing instruments, which include verbal rating scales, numerical rating scales, and graphical scales.

Results:

Brief self-report measures of pain intensity and pain interference were selected for inclusion in the core NIH Toolbox for use with adults. A 0 to 10 numerical rating scale was recommended for measuring pain intensity, and a 6-item Patient Reported Outcome Measurement Information System (PROMIS) short form for measuring pain interference. The 8-item PROMIS Pediatric Pain Interference measure was recommended as a supplemental measure. No specific measure was recommended for measuring pain intensity in children.

Conclusions:

Core and supplemental measures were recommended for the NIH Toolbox. Additional measures were reviewed for investigators who seek tools for measuring pain intensity in pediatric samples.

Pain is an important component of health and function. The NIH Toolbox somatosensation team took responsibility for considering the best methods for evaluating pain in the general population. In the International Classification of Functioning, Disability and Health, sensory functions and pain are grouped together as body functions; however, sensation of pain is distinguished from sensory functions such as proprioception or touch, as well as functions related to temperature and other stimuli.1 The definition of somatosensory function includes the “detection, discrimination, and recognition” of pain (Dunn et al., this issue). However, pain is more than a biological process and can be integral to function, role participation, and overall quality of life. As such, its assessment often becomes a primary end point in clinical trials and treatment effectiveness studies. This led the Toolbox team to consider pain and its assessment in parallel with somatosensory function and to dedicate separate manuscripts to discussions of pain and somatosensation.

The science of pain measurement has benefited from recent advances in measurement approaches and applications.24 The field of outcomes research has well-developed, self-reported pain measures that have been validated in a range of acute and chronic medical conditions. For this reason, the team chose not to develop new pain measures but to adopt existing instruments that would add to the battery of tests included in the NIH Toolbox. In this article, we describe the importance of pain to the assessment of health and discuss its multidimensional nature. We identify pain subdomains of particular interest to users of the NIH Toolbox and review current strategies for measuring those subdomains in adults and in children. This review is intended to provide users with a context for understanding the measurement of pain subdomains. Our recommendations for the NIH Toolbox core and supplemental measures of pain are summarized.

PAIN AND HEALTH ASSESSMENT

Pain has been defined as an “unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.”5,6 The International Association for the Study of Pain has called unrelieved pain “a major global healthcare problem.”7

Experiences and assessments of pain are often characterized as acute, chronic, or persistent.8 Acute pain comes on abruptly and lasts a relatively short time. Such pain serves as a warning of an injury or sudden illness and may be mild or severe.9 Chronic pain extends beyond the expected period of healing, often designated as persisting 6 months or more. A national survey estimated the point prevalence of chronic pain at >30%, with half of these reporting daily pain and 32% reporting 3-month average pain ≥7 on a scale of 0 to 10.10 Not only is pain highly prevalent, its impact on quality of life is far-reaching. Pain interferes with sleep, makes activities of daily living more difficult, limits social engagement, and is financially burdensome to individuals and their families (see, for example, references 11–15). Furthermore, pain causes changes in neural function that outlast the precipitating disease or injury. Although typically triggered by injury or disease, chronic pain “becomes independent; it takes on a life of its own.”16 Thus, pain has been described as “a disease in its own right.”16 The prevalence, impact, and psychological and physiologic consequences of unrelieved chronic pain make it a critical domain in the assessment of health.

Because pain has a variety of origins and expressions, it is best described as multidimensional.17 Subdomains include pain intensity and temporal patterns, description and localization, and interference with quality of life, affect, and behavior. A full assessment of pain might include measures of each of these subdomains. For the purposes of the NIH Toolbox, investigators focused on the 2 most frequently assessed subdomains: pain intensity and pain interference.18 Below we summarize common strategies for the measurement of pain intensity and interference within adult and pediatric populations.

PAIN INTENSITY

Measuring pain intensity of adults.

Pain intensity, defined as the “magnitude of experienced pain,”19 is a narrow construct often measured using a 1-item scale. To measure pain intensity of adults, the most common strategies are verbal rating scales (VRSs), numerical rating scales (NRSs), visual analog scales (VASs), and graphical scales. With VRSs, participants select from among pain descriptors (e.g., mild, moderate, severe). VASs present a line on which respondents mark the point they believe most descriptive of their pain. The line has verbal descriptors, “anchors,” at the ends (e.g., “no pain” or “extreme pain”). Sometimes descriptors between anchors are included. NRSs ask respondents to pick a number that represents their pain level (e.g., 0–10). Graphical scales represent graduated levels of pain as drawings (e.g., faces) that express increasing levels of distress. Participants select the picture that best represents their level of pain. Graphical scales have verbal or numerical descriptors as anchors and may have one or more descriptors between anchors.

An extensive review on behalf of the European Palliative Care Research Collaborative examined 54 published studies that compared at least 2 of 3 different categories of scales (i.e., VRSs, VASs, NRSs) in acute or chronic pain.20 Across the 54 studies, 131 unique measures were cataloged: 59 VASs, 39 VRSs, and 33 NRSs. Most of the reviewed studies recommended no particular category of pain-intensity scaling. Of those that did, 3 suggested a scale from a category other than NRSs, VRSs, or VASs; 11 recommended using NRSs; 7, VRSs; and 4, VASs. Correlations are typically high between scores from different kinds of pain-intensity measures,20 but substantial nonequivalence between individual scores has been documented,2124 and this nonequivalence in scores varied in direction.22,23

Measuring pain intensity of children.

Even more challenging than measuring the pain of adults is measuring pain intensity experienced and reported by children. Strategies include self-report, physiologic indicators, and behavioral measures (including proxy report).2527 These different approaches produce nonequivalent results that only weakly correlate with each other.26 The weak associations suggest that they may be assessing distinct constructs.26

As with adults, self-report is accepted as the “gold standard” for measuring the pain intensity of children.25,28 Graphical scales are arguably less abstract than NRS and VAS measures and often are used for measuring children's pain intensity. There are a number of “faces pain scales” that include drawings of faces to suggest graduated levels of distress (e.g., smiling face at one end; face with tears at the other). Tomlinson et al.28 conducted a review of self-reported pain-intensity measures for children and found that children prefer faces scales to other single-item measures. In their review, the Wong-Baker Faces Pain Rating Scale (WBFPRS)29 was preferred by children in studies that compared more than one faces scale.

NIH Toolbox pain-intensity measures.

For measuring the pain intensity of adults, the NIH Toolbox adopted a single-item measure for inclusion within its core battery of assessments. The item, “In the past 7 days, how would you rate your pain on average?” is scored on a 0 to 10 NRS in which 0 = no pain and 10 = worst imaginable pain. The 0 to 10 NRS is frequently used in clinical studies, and its validity has been demonstrated empirically.19 Adding to its usefulness are estimations made within different clinical populations, based on the 0 to 10 scale, of cut-scores for different levels of pain (e.g., mild, moderate, severe).3032 However, this recommendation is qualified by the empirical findings of nonequivalence between individual scores.2124 No measure of pain intensity can fully capture individuals' experiences of pain.

Although the NIH Toolbox only addressed assessment of average pain intensity, it is important to note that “worst pain” also has been suggested as a clinical trial end point.33,34 Worst pain may be measured by substituting the phrase “on average” with a phrase such as “at its worst.”

For the measurement of children's pain intensity, no specific supplemental measure was identified for the NIH Toolbox. Although research indicates that children prefer a faces scale,28 the WBFPRS has weaknesses. The anchor faces of the WBFPRS (a smiley face and a face with tears) may confound affect with pain intensity, especially in younger children.28

PAIN INTERFERENCE MEASUREMENT

Pain interference may be thought of as a functional consequence of pain intensity. There is substantial empirical and clinical evidence that the 2 are distinct constructs and that each provides valuable information.18 Pain intensity is a relatively narrow domain, but pain interference is broader, multifaceted, and associated with pain disability. The subdomains typically tracked by self-reported pain interference measures include impact on physical function, work, recreation, social activities, family roles, activities of daily living, and sleep.

Measuring pain interference in adults.

There are many published measures of pain interference for use in adult populations (see, for example, references 35–38). However, with few exceptions,3,35,39 pain interference measures have been developed using classic test theory approaches. Compared with classic psychometric approaches, newer strategies such as item response theory (IRT) allow for finer-grade evaluations of measures. Psychometric assessments are made at the individual item level, not at the scale level as with classic test theory. Furthermore, the precision of scores at different levels of pain interference can be assessed with IRT methods by calculating scale information.40 The Patient Reported Outcome Measurement Information System (PROMIS) initiative applied IRT methods in developing the PROMIS Pain Interference item bank.3 As described on the PROMIS Web site (http://www.nihpromis.org), “The pain interference item bank measures the self-reported consequences of pain on relevant aspects of one's life. This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities ...”

Measuring pain interference in children.

Although substantial psychometric attention has been given to the measurement of children's pain intensity, the same is not true of the measurement of children's pain interference. Two exceptions are the Child Activity Limitations Interview41 and the PROMIS Pediatric Pain Interference Scale.42 An advantage of the PROMIS scale over the Child Activity Limitations Interview is the fact that it was developed using modern psychometric methods (IRT), and the items of the bank were tested for differential item function (DIF) between boys and girls of differing ages. DIF exists when, after holding level of pain interference constant, the probabilities of different responses to an item vary by subgroup. DIF is a threat to measurement validity because the trait being measured should drive how respondents answer a question, not their membership in a particular demographic or clinical subgroup. An 8-item subscale assesses pain impact on children's sleep, attention, mobility (e.g., walking, running, standing), ability to have fun, schoolwork, and affect (e.g., anger when in pain). A recently published study with 8- to 17-year-old children with cancer found evidence for the feasibility and validity of the PROMIS pediatric measures, including the PROMIS Pain Interference measure.

NIH Toolbox pain interference measures.

For the measurement of pain interference in adults, the NIH Toolbox adapted the PROMIS Pain Interference v1.0–Pain Interference 6a (https://www.assessmentcenter.net). The 6 items of this short form ask, “How much did pain interfere with: a) your day to day activities, b) work around the home, c) your ability to participate in social activities, d) your household chores, e) the things you usually do for fun, and f) your enjoyment of social activities?” Each item is scored from 1 to 5, where 1 = not at all, 2 = a little bit, 3 = somewhat, 4 = quite a bit, and 5 = very much. The item set in short form 6a includes 6 of the 10 most “discriminating” items in the item bank; that is, the items that best distinguish among different levels of pain interference. Items with greater discrimination yield more precision in estimating individuals' pain interference levels.

The NIH Toolbox adopted the PROMIS Pediatric Pain Interference measure for use in measuring self-reported pain interference in children. To date, clinical validity of this measure has been evidenced in children aged 8 to 17 years. Future studies need to evaluate whether the measure retains its validity and feasibility in younger clinical populations.

CONCLUSION

In this article, we present a context for understanding the importance of pain and review strategies for its measurement. Two measures were adopted into the NIH Toolbox core battery for adults: a 0 to 10 NRS for measuring pain intensity and a 6-item PROMIS Pain Interference short form. The PROMIS Pediatric Pain Interference is included as a supplemental measure for measuring children's pain interference. No particular scale for measuring pain intensity in pediatric populations was recommended.

GLOSSARY

DIF
differential item function
IRT
item response theory
NRS
numerical rating scale
PROMIS
Patient Reported Outcome Measurement Information System
VAS
visual analog scale
VRS
verbal rating scale
WBFPRS
Wong-Baker Faces Pain Rating Scale

AUTHOR CONTRIBUTIONS

Dr. Cook: manuscript concept and design. Dr. Dunn, Dr. Griffith, Dr. Morrison, Dr. Tanquary, Dr. Sabata, Dr. Victorson: domain conceptualization and critical review of the manuscript for important intellectual content. Dr. Carey: study supervision, domain conceptualization and critical review of the manuscript for important intellectual content, domain conceptualization, and critical review of the manuscript for important intellectual content. Dr. MacDermid, Dr. Dudgeon, Dr. Gershon: study supervision, domain conceptualization and critical review of the manuscript for important intellectual content.

STUDY FUNDING

This study is funded in whole or in part with Federal funds from the Blueprint for Neuroscience Research, NIH, under contract no. HHS-N-260-2006-0000-7-C.

DISCLOSURE

K. Cook has received financial support from Center for Psychiatric Rehabilitation Boston University, InvivoData, Xenoport, BrightOucome, the NIH, Veteran's Affairs Research and Development, National Institute on Disability and Rehabilitation Research (NIDDR), and Agency for Healthcare Research and Quality (AHRQ). In addition to Toolbox, Dr. Cook receives other funding from NIH (5RC1NR011804-02 and 1U5AR057943-01). She also is currently supported by grants from NIDDR (H133B090024) and AHRQ (1R03HS020700-01). W. Dunn is the author of the Sensory Profile measures, which are published by Pearson Inc. Pearson Inc. owns the copyright on these tests, and Dr. Dunn receives a royalty when they are sold. J. Griffith has received financial support from NorthShore University HealthSystem, the Cleveland Clinic Foundation/Teva Neurosciences, Inc., Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc., the NIH, the Department of Defense (DOD)–United States Army, and the FWO, Belgium. In addition to NIH Toolbox funding, he receives funding from the NIH for other research (grant U01 DK082342). He has also been a paid consultant to Dr. Kathryn Grant of DePaul University, and maintains a clinical psychology practice for which he bills for his services. T. Morrison, J. Tanquary, and D. Sabata report no disclosures. D. Victorson holds stock options in Eli Lilly and Company, received an honoraria for serving on the Steering Committee of the Reeve Neuro-Recovery Network, was funded by NIH contracts HHSN265200423601C and HHS-N-260-2006-00007-C and grants R01HD054569-02NIDRR, 1U01NS056975-01, R01 CA104883, received support from the American Cancer Society (national and Illinois Division) for research in prostate cancer, received institutional support from NorthShore University HealthCare System for research in prostate cancer, received institutional support from the Medical University of South Carolina for sarcoidosis research, and received institutional support from the Northwestern Medical Faculty Foundation for urology research. L. Carey is supported by an Australian Research Council Future Fellowship (FT0992299) and was previously supported by a National Health and Medical Research Council of Australia Career Development Award (307905). Dr. Carey is an expert consultant for the NIH Toolbox Project. J. MacDermid and B. Dudgeon report no disclosures. R. Gershon has received personal compensation for activities as a speaker and consultant with Sylvan Learning, Rockman, and the American Board of Podiatric Surgery. He has several grants awarded by NIH: N01-AG-6-0007, 1U5AR057943-01, HHSN260200600007, 1U01DK082342-01, AG-260-06-01, HD05469; NINDS: U01 NS 056 975 02; NHLBI K23: K23HL085766; NIA: 1RC2AG036498-01; NIDRR: H133B090024; OppNet: N01-AG-6-0007.

REFERENCES

1. Cieza A, Stucki G, Weigl M, et al. ICF core sets for chronic widespread pain. J Rehabil Med 2004;36:63–68. [PubMed]
2. Revicki DA, Chen WH, Harnam N, et al. Development and psychometric analysis of the PROMIS pain behavior item bank. Pain 2009;146:158–169. [PMC free article] [PubMed]
3. Amtmann D, Cook KF, Jensen MP, et al. Development of a PROMIS item bank to measure pain interference. Pain 2010;150:173–182. [PMC free article] [PubMed]
4. Cella D, Riley W, Stone A, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol 2010;63:1179–1194. [PMC free article] [PubMed]
5. IASP Task Force on Taxonomy Part III: pain terms—a current list with definitions and notes on usage. In: Merskey H, Bogduk N, editors. , editors. Classification of Chronic Pain, 2nd ed Seattle: IASP Press; 1994:209–214.
6. IASP Task Force on Taxonomy IASP Taxonomy [online]. Available at: http://www.iasp-pain.org/AM/Template.cfm?Section=Pain_DefinitionsAccessed February 8, 2013.
7. International Association for the Study of Pain Unrelieved pain is a major healthcare problem [online]. Available at: http://www.iasp-pain.org/AM/Template.cfm?Section=Home&Template=/CM/ContentDisplay.cfm&ContentID=2908. Accessed April 13, 2012.
8. Institute of Medicine of the National Academies Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies; 2011. [PubMed]
9. Berry PH, Dahl JL. The new JCAHO pain standards: implications for pain management nurses. Pain Manag Nurs 2000;1:3–12. [PubMed]
10. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 2010;11:1230–1239. [PubMed]
11. Mystakidou K, Parpa E, Tsilika E, et al. The relationship of subjective sleep quality, pain, and quality of life in advanced cancer patients. Sleep 2007;30:737–742. [PubMed]
12. Schirbel A, Reichert A, Roll S, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol 2010;16:3168–3177. [PMC free article] [PubMed]
13. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443–2454. [PubMed]
14. Ramstad K, Jahnsen R, Skjeldal OH, Diseth TH. Parent-reported participation in children with cerebral palsy: the contribution of recurrent musculoskeletal pain and child mental health problems. Dev Med Child Neurol 2012;54:829–835. [PubMed]
15. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2012. [PubMed]
16. Niv D, Devor M. Chronic pain as a disease in its own right. Pain Pract 2004;4:179–181. [PubMed]
17. Merskey H, Bogduk N, editors. , editors. Classification of Chronic Pain, 2nd edSeattle, WA: IASP Press; 1994.
18. Fayers PM, Hjermstad MJ, Klepstad P, et al. The dimensionality of pain: palliative care and chronic pain patients differ in their reports of pain intensity and pain interference. Pain 2011;152:1608–1620. [PubMed]
19. Jensen MP, Karoly P. Measurement of cancer pain via patient self-report. In: Chapman CR, Foley KM, editors. , editors. Current and Emerging Issues in Cancer Pain: Research and Practice. New York: Raven Press; 1993:193–218.
20. Hjermstad MJ, Fayers PM, Haugen DF, et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage 2011;41:1073–1093. [PubMed]
21. Carpenter JS, Brockopp D. Comparison of patients' ratings and examination of nurses' responses to pain intensity rating scales. Cancer Nurs 1995;18:292–298. [PubMed]
22. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 1997;72:95–97. [PubMed]
23. Ekblom A, Hansson P. Pain intensity measurements in patients with acute pain receiving afferent stimulation. J Neurol Neurosurg Psychiatry 1988;51:481–486. [PMC free article] [PubMed]
24. Heikkinen K, Salantera S, Kettu M, Taittonen M. Prostatectomy patients' postoperative pain assessment in the recovery room. J Adv Nurs 2005;52:592–600. [PubMed]
25. von Baeyer CL, Spagrud LJ. Systematic review of observational (behavioral) measures of pain for children and adolescents aged 3 to 18 years. Pain 2007;127:140–150. [PubMed]
26. Walco GA, Conte PM, Labay LE, Engel R, Zeltzer LK. Procedural distress in children with cancer: self-report, behavioral observations, and physiological parameters. Clin J Pain 2005;21:484–490. [PubMed]
27. Zhou H, Roberts P, Horgan L. Association between self-report pain ratings of child and parent, child and nurse and parent and nurse dyads: meta-analysis. J Adv Nurs 2008;63:334–342. [PubMed]
28. Tomlinson D, von Baeyer CL, Stinson JN, Sung L. A systematic review of faces scales for the self-report of pain intensity in children. Pediatrics 2010;126:e1168–e1198. [PubMed]
29. Wong DL, Baker CM. Pain in children: comparison of assessment scales. Pediatr Nurs 1988;14:9–17. [PubMed]
30. Gerbershagen HJ, Rothaug J, Kalkman CJ, Meissner W. Determination of moderate-to-severe postoperative pain on the numeric rating scale: a cut-off point analysis applying four different methods. Br J Anaesth 2011;107:619–626. [PubMed]
31. Kapstad H, Hanestad BR, Langeland N, Rustoen T, Stavem K. Cutpoints for mild, moderate and severe pain in patients with osteoarthritis of the hip or knee ready for joint replacement surgery. BMC Musculoskelet Disord 2008;9:55. [PMC free article] [PubMed]
32. Li KK, Harris K, Hadi S, Chow E. What should be the optimal cut points for mild, moderate, and severe pain? J Palliat Med 2007;10:1338–1346. [PubMed]
33. Farrar JT, Pritchett YL, Robinson M, Prakash A, Chappell A. The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain 2010;11:109–118. [PubMed]
34. Koller A, Miaskowski C, De Geest S, Opitz O, Spichiger E. Supporting self-management of pain in cancer patients: methods and lessons learned from a randomized controlled pilot study. Eur J Oncol Nurs 2013;17:1–8. [PubMed]
35. Becker J, Schwartz C, Saris-Baglama RN, Kosinski M, Bjorner JB. Using item response theory (IRT) for developing and evaluating the Pain Impact Questionnaire (PIQ-6TM). Pain Med 2007;8:S129–S144.
36. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129–138. [PubMed]
37. Kerns RD, Turk DC, Rudy TE. The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain 1985;23:345–356. [PubMed]
38. Pollard CA. Preliminary validity study of the pain disability index. Percept Mot Skills 1984;59:974. [PubMed]
39. Lai JS, Dineen K, Reeve BB, et al. An item response theory-based pain item bank can enhance measurement precision. J Pain Symptom Manage 2005;30:278–288. [PubMed]
40. Hays RD, Bjorner JB, Revicki DA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res 2009;18:873–880. [PMC free article] [PubMed]
41. Palermo TM, Lewandowski AS, Long AC, Burant CJ. Validation of a self-report questionnaire version of the Child Activity Limitations Interview (CALI): the CALI-21. Pain 2008;139:644–652. [PMC free article] [PubMed]
42. Varni JW, Stucky BD, Thissen D, et al. PROMIS Pediatric Pain Interference Scale: an item response theory analysis of the pediatric pain item bank. J Pain 2010;11:1109–1119. [PMC free article] [PubMed]

Articles from Neurology are provided here courtesy of American Academy of Neurology